Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential

Cristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fernandez C, van Halsema CL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	antiretroviral therapy integrase inhibitors non-nucleoside reverse transcriptase inhibitors Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/a09d2af3a9054c7f880cb8e75d206c4b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a09d2af3a9054c7f880cb8e75d206c4b
record_format	dspace
spelling	oai:doaj.org-article:a09d2af3a9054c7f880cb8e75d206c4b2021-12-02T04:14:31ZEvaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential1179-1373https://doaj.org/article/a09d2af3a9054c7f880cb8e75d206c4b2019-07-01T00:00:00Zhttps://www.dovepress.com/evaluating-cabotegravirrilpivirine-long-acting-injectable-in-the-treat-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Cristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. Adding to the increasing body of evidence for newer two-drug combinations, phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most importantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-weekly injections, despite frequent injection-site reactions. Key outstanding questions include management of missed or delayed dosing, drug interactions and management of virological failure, as well as the efficacy of cabotegravir and rilpivirine in all HIV-1 subtypes. We describe clinical evidence to date and efficacy and challenges in selected populations, including women; those with prior virological failure; individuals with a history of difficulty adhering to oral therapy and individuals with co-infections. We await real-world data and longer-term evidence while moving forward to this new era of antiretroviral therapy.Keywords: antiretroviral therapy, integrase inhibitors, non-nucleoside reverse transcriptase inhibitorsFernandez Cvan Halsema CLDove Medical Pressarticleantiretroviral therapyintegrase inhibitorsnon-nucleoside reverse transcriptase inhibitorsImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 11, Pp 179-192 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	antiretroviral therapy integrase inhibitors non-nucleoside reverse transcriptase inhibitors Immunologic diseases. Allergy RC581-607
spellingShingle	antiretroviral therapy integrase inhibitors non-nucleoside reverse transcriptase inhibitors Immunologic diseases. Allergy RC581-607 Fernandez C van Halsema CL Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
description	Cristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. Adding to the increasing body of evidence for newer two-drug combinations, phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most importantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-weekly injections, despite frequent injection-site reactions. Key outstanding questions include management of missed or delayed dosing, drug interactions and management of virological failure, as well as the efficacy of cabotegravir and rilpivirine in all HIV-1 subtypes. We describe clinical evidence to date and efficacy and challenges in selected populations, including women; those with prior virological failure; individuals with a history of difficulty adhering to oral therapy and individuals with co-infections. We await real-world data and longer-term evidence while moving forward to this new era of antiretroviral therapy.Keywords: antiretroviral therapy, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors
format	article
author	Fernandez C van Halsema CL
author_facet	Fernandez C van Halsema CL
author_sort	Fernandez C
title	Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_short	Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_full	Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_fullStr	Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_full_unstemmed	Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_sort	evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of hiv infection: emerging data and therapeutic potential
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/a09d2af3a9054c7f880cb8e75d206c4b
work_keys_str_mv	AT fernandezc evaluatingcabotegravirrilpivirinelongactinginjectableinthetreatmentofhivinfectionemergingdataandtherapeuticpotential AT vanhalsemacl evaluatingcabotegravirrilpivirinelongactinginjectableinthetreatmentofhivinfectionemergingdataandtherapeuticpotential
_version_	1718401389900595200

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential

Ejemplares similares